Page last updated: 2024-12-07

epoxiconazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

epoxiconazole : A racemate composed of equimolar amounts of (2S,3R)- and (2R,3S)-epoxiconazole. A broad-spectrum fungicide for control of diseases caused by Ascomycetes, Basidiomycetes and Deuteromycetes. Epoxiconazole is moderately toxic to birds, honeybees, earthworms and most aquatic organisms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-{[3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole : An epoxide that is oxirane substituted by a 2-chlorophenyl, 4-fluorophenyl and a 1H-1,2,4-triazol-1-ylmethyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3317081
CHEMBL ID3184033
CHEBI ID83758
SCHEMBL ID21976
MeSH IDM0284102

Synonyms (32)

Synonym
AC-396
135319-73-2
epoxiconazole
106325-08-0
1-[[3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl]-1,2,4-triazole
1-[[3-(2-chlorophenyl)-2-(4-fluorophenyl)-2-oxiranyl]methyl]-1,2,4-triazole
A806918
NCGC00248222-01
NCGC00254849-01
cas-133855-98-8
dtxcid9020372
tox21_300947
FT-0631151
AKOS015888796
SCHEMBL21976
1-{[3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl}-1h-1,2,4-triazole
CHEBI:83758 ,
CHEMBL3184033
ZMYFCFLJBGAQRS-UHFFFAOYSA-N
1-[[(2s,3s)-3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl]-1,2,4-triazole
(2rs,3sr)-1-[3-(2-chlorophenyl)-2,3-epoxy-2-(4-fluorophenyl)propyl]-1h-1,2,4-triazole
1h-1,2,4-triazole,1-[[3-(2-chlorophenyl)-2-(4-fluorophenyl)-2-oxiranyl]methyl]-
Q27157181
1-((3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl)methyl)-1h-1,2,4-triazole
BCP14362
ec-406-850-2
bas480f
bas-480f
ec 406 850 2
DTXSID901034223
Z3234876548
EN300-7480082

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse effects were observed in young and adult male offspring from the group exposed to the highest dose of the mixture."( Persistent developmental toxicity in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides.
Axelstad, M; Berthelsen, LO; Boberg, J; Christiansen, S; Hass, U; Isling, LK; Jacobsen, PR; Mandrup, KR; Vinggaard, AM, 2012
)
0.38
"The toxicological relevance of effects observed at molecular stage, which occur at dose levels well below classical no-observed adverse effect levels is currently subject to controversial scientific debate."( Hepatotoxic effects of (tri)azole fungicides in a broad dose range.
Haider, W; Heise, T; Knebel, C; Kneuer, C; Marx-Stoelting, P; Niemann, L; Pfeil, R; Rieke, S; Schmidt, F, 2015
)
0.42
" The excessive application of this pesticide may result in a variety of adverse effects on non-target organisms, including humans."( Oxidative stress, genotoxicity, biochemical and histopathological modifications induced by epoxiconazole in liver and kidney of Wistar rats.
Abid-Essefi, S; Ammar, O; Ghali, FB; Hallara, E; Hamdi, H; Houas, Z; Klifi, A; Najjar, MF; Othmène, YB, 2019
)
0.51
" We conclude that the PluriBeat assay is a novel method for predicting chemicals' adverse effects on embryonic development."( A novel human pluripotent stem cell-based assay to predict developmental toxicity.
Emnéus, JK; Holst, B; Lauschke, K; Meiser, I; Neubauer, JC; Rasmussen, MA; Rosenmai, AK; Schmidt, K; Taxvig, C; Vinggaard, AM, 2020
)
0.56
"It is acknowledged that azole fungicides may release into the environment and pose potential toxic risks."( Toxicity interactions of azole fungicide mixtures on Chlorella pyrenoidosa.
Deng, ZG; Huang, FL; Liang, YP; Liu, M; Mo, LY; Qin, LT; Zeng, HH, 2023
)
0.91

Bioavailability

The aim of this study was to assess the bioavailability of epoxiconazole (EPO) and difenoconazole in rice plants. Oleic acid-embedded cellulose acetate membranes (OECAMs) were developed. The membranes were tested on earthworms (Eisenia fetida)

ExcerptReferenceRelevance
" This study aims to propose a mild extraction method to evaluate the bioavailability of the fungicide epoxiconazole to the earthworm Aporrectodea icterica."( Evaluation of epoxiconazole bioavailability in soil to the earthworm Aporrectodea icterica.
Awad, P; Delarue, G; Fraillon, F; Nélieu, S; Ollivier, E; Pelosi, C, 2016
)
0.43
" However, data on their environmental behaviour and bioavailability to soil organisms are surprisingly scarce."( Ageing effect on conazole fungicide bioaccumulation in arable soils.
Bílková, Z; Hofman, J; Peštálová, N; Sedláček, P; Šudoma, M, 2021
)
0.62
" For low-sorbing soil variants, the bioaccumulation was also influenced by the type of biochar corresponding to its sorbing potential and the possible effect on the bioavailability of the fungicides."( Conazole fungicides epoxiconazole and tebuconazole in biochar amended soils: Degradation and bioaccumulation in earthworms.
Bielská, L; Bílková, Z; Bošković, N; Hofman, J; Ribitsch, D; Škulcová, L; Soja, G; Šudoma, M, 2021
)
0.62
" Oleic acid-embedded cellulose acetate membranes (OECAMs) were developed to evaluate the bioavailability of epoxiconazole (EPO) to earthworms (Eisenia fetida)."( Accumulation of epoxiconazole from soil via oleic acid-embedded cellulose acetate membranes and bioavailability evaluation in earthworms (Eisenia fetida).
Chen, Y; Dong, F; Liu, X; Wu, X; Xu, J; Yuan, S; Zheng, Y, 2022
)
0.72
"The aim of this study was to assess the bioavailability of epoxiconazole (EPO) and difenoconazole (DIF) in rice plants by evaluating their uptake, translocation, and accumulation."( Bioavailability evaluation of epoxiconazole and difenoconazole in rice and the influence of dissolved organic matter in reducing uptake and translocation.
Chen, Y; Liu, X; Mao, L; Zhang, L; Zheng, Y; Zhou, Y; Zhu, L, 2023
)
0.91

Dosage Studied

Rats were dosed with epoxiconazole (15 or 50 mg/kg bw/day) during pregnancy and continued during lactation. We decided to profile the VOCs from secondary metabolism of oilseed rape.

ExcerptRelevanceReference
" Rats were dosed with epoxiconazole (15 or 50 mg/kg bw/day) or tebuconazole (50 or 100 mg/kg bw/day) during pregnancy from gestational day (GD) 7 and continued during lactation until postnatal day (PND) 16."( Endocrine-disrupting activities in vivo of the fungicides tebuconazole and epoxiconazole.
Andeasen, HR; Axelstad, M; Boberg, J; Dalgaard, M; Hass, U; Taxvig, C; Vinggaard, AM, 2007
)
0.34
" This as well as the predictability of the combination effects based on dose-additivity modelling will be studied further in a large dose-response study."( Combined exposure to endocrine disrupting pesticides impairs parturition, causes pup mortality and affects sexual differentiation in rats.
Boberg, J; Christiansen, S; Hass, U; Jacobsen, PR; Nellemann, C, 2010
)
0.36
" Pregnant and lactating rat dams were dosed with a mixture of the five pesticides at three different doses, or with the individual pesticides at one of two doses."( Persistent developmental toxicity in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides.
Axelstad, M; Berthelsen, LO; Boberg, J; Christiansen, S; Hass, U; Isling, LK; Jacobsen, PR; Mandrup, KR; Vinggaard, AM, 2012
)
0.38
" The stereoselectivity in bioaccumulation in the 2mg/kg dosage was not obvious compared to the 20mg/kg group."( Stereoselectivity in bioaccumulation and excretion of epoxiconazole by mealworm beetle (Tenebrio molitor) larvae.
Gao, Y; Guo, B; Li, J; Li, Y; Liu, C; Lv, X; Wang, H, 2014
)
0.4
" Three different experimental setups were applied: A standard 48h acute toxicity test, an adapted 48h test using passive dosing for constant chemical exposure concentrations, and a 14-day test."( Determining lower threshold concentrations for synergistic effects.
Bjergager, MA; Cedergreen, N; Dalhoff, K; Kretschmann, A; Mayer, P; Nørgaard, KB, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency36.41320.006038.004119,952.5996AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency35.04870.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency46.61370.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency30.63790.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency34.37620.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency46.22710.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency43.25960.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency15.35530.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency63.31630.000229.305416,493.5996AID1259244; AID1259248; AID743078; AID743079; AID743080; AID743091
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.19490.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency42.73360.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency3.85710.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency30.63790.000323.4451159.6830AID743065; AID743067
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (121)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (0.83)18.2507
2000's20 (16.53)29.6817
2010's63 (52.07)24.3611
2020's37 (30.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other121 (99.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]